Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
The histologic and cytologic distinction of malignant mesothelioma from carcinomas metastatic to the pleura or peritoneum is often problematic. For this reason immunologic methods are being increasingly used as diagnostic adjuncts. This review summarizes 40 studies on the expression of carcinoembryonic antigen in mesotheliomas and in lung and other carcinomas involving the pleura or peritoneum. Carcinoembryonic antigen was identified immunohistochemically in 11% of mesotheliomas and in 84% of carcinomas examined and immunocytochemically (in serous effusions) in 4% and 58%, respectively. In serum and in pleural or ascitic fluid, significantly elevated levels of carcinoembryonic antigen are commonly associated with (lung) carcinomas but rarely with mesotheliomas. Thus, together with identification of the antigen in serum, pleural fluid, or ascitic fluid, immunohistochemical and immunocytochemical techniques for detecting carcinoembryonic antigen provide a valuable aid for distinguishing malignant mesothelioma from metastatic carcinomas.
Mezger
J
J
Department of Internal Medicine III, Klinikum Grosshadern, Munich, Federal Republic of Germany.
Lamerz
R
R
Permanetter
W
W
D014408:Biomarkers, Tumor / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D003937:Diagnosis, Differential; D006801:Humans; D007150:Immunohistochemistry; D008654:Mesothelioma / Q000175:diagnosis*; D015201:Meta-Analysis as Topic; D010534:Peritoneal Neoplasms / Q000175:diagnosis / Q000556:secondary; D016066:Pleural Effusion, Malignant / Q000175:diagnosis / Q000276:immunology; D010997:Pleural Neoplasms / Q000175:diagnosis / Q000556:secondary
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen